Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Trulicity is another type of GLP-1 receptor agonist that is effective for reducing blood sugar levels and heart disease risk in people with diabetes. Like Ozempic, it’s an injectable medication ...

Meanwhile, Lilly also confirmed that it will start running a head-to-head cardiovascular outcomes trial for Trulicity and one of its pipeline diabetes candidates – dual GIP/GLP1 agonist tirzepat ...

New phase 3b trial results show Lilly’s Trulicity has helped type 2 diabetes patients already taking an SGLT2 inhibitor but whose blood sugar was inadequately controlled. The AWARD trial showed ...

Novo Nordisk expects Ozempic, which has been on the market since 2017, will be on Medicare's list of drugs to negotiate ...

Popular diabetes drugs such as Ozempic and Trulicity are among 25 drugs Medicare has spent the most on but hasn't yet selected for price negotiation, according to a report released Thursday.